Search Results

You are looking at 61 - 70 of 89 items for :

  • "Ovarian carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Mary B. Daly, Robert Pilarski, Jennifer E. Axilbund, Saundra S. Buys, Beth Crawford, Susan Friedman, Judy E. Garber, Carolyn Horton, Virginia Kaklamani, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer Litton, Lisa Madlensky, P. Kelly Marcom, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Boris Pasche, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C. Voian, Jeffrey N. Weitzel, Alison Whelan, Georgia L. Wiesner, Mary A. Dwyer, and Rashmi Kumar

hamartoma-tumor syndrome . Arch Dermatol 2006 ; 142 : 625 – 632 . 28. Jazaeri AA Lu K Schmandt R . Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma . Mol Carcinog 2003 ; 36 : 53 – 59 . 29

Full access

Renata R. Urban, Hao He, Rafael Alfonso-Cristancho, Melissa M. Hardesty, and Barbara A. Goff

Wiechert A . Patient, treatment and discharge factors associated with hospital readmission within 30 days after surgical cytoreduction for epithelial ovarian carcinoma . Gynecol Oncol 2013 ; 130 : 407 – 410 . 27. FDA Draft Guidance on

Full access

Michaela A. Dinan, Bradford R. Hirsch, and Gary H. Lyman

epithelial ovarian carcinoma—a cost-effectiveness analysis . Int J Gynecol Cancer 2007 ; 17 : 1019 – 1024 . 38. Fust K Li X Maschio M . Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent

Full access

Alok A. Khorana

-bearing microparticles are associated with venous thromboembolic events in malignancy . Clin Cancer Res 2009 ; 15 : 6830 - 6840 . 24 Han LY Landen CN Jr Kamat AA . Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian

Full access

Deborah J. MacDonald, Kathleen R. Blazer, and Jeffrey N. Weitzel

Yap TA . Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers . N Engl J Med 2009 ; 361 : 1 – 12 . 12. Lynch HT Casey MJ Snyder CL . Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology

Full access

Lyndsay J. Willmott, Daniele A. Sumner, and Bradley J. Monk

is a monoclonal antibody directed against VEGF-A. It was the first clinically available antiangiogenic agent in the United States 19 and has been successfully studied in many solid tumors, including colon, lung, breast, renal, brain, and ovarian

Full access

Tomas G. Lyons and Mark E. Robson

. 13. Gelmon KA Tischkowitz M Mackay H . Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study . Lancet Oncol

Full access

Talia Golan and Milind Javle

response and progression-free survival were demonstrated when treated with checkpoint inhibitors. 45 BRCA1/2 mutated high-grade serous ovarian carcinoma is associated with a higher mutation burden compared with non– BRCA1/2 -mutated tumors, higher

Full access

Alan P. Venook, Maria E. Arcila, Al B. Benson III, Donald A. Berry, David Ross Camidge, Robert W. Carlson, Toni K. Choueiri, Valerie Guild, Gregory P. Kalemkerian, Razelle Kurzrock, Christine M. Lovly, Amy E. McKee, Robert J. Morgan, Anthony J. Olszanski, Mary W. Redman, Vered Stearns, Joan McClure, and Marian L. Birkeland

broad-spectrum mass spectrometry genotyping . J Mol Diagn 2011 ; 13 : 64 – 73 . 35. Kabiawu Ajise OE Feldstein JT Soslow R . Assessment of BRAF V600E mutation status by immunohistochemistry in lung and ovarian carcinomas [abstract] . Mod

Full access

Lois Ramondetta

. Thaker PH Han LY Kamat AA . Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma . Nat Med 2006 ; 12 : 939 – 944 . 55. Wong HP Yu L Lam EK . Nicotine promotes colon tumor growth and angiogenesis